DOI: 10.12890/2025_005464
Unexpected falsely high vancomycin concentrations in a patient with endocarditis during routine therapeutic drug monitoring
Authors
mariadelrosario.salas@salud.madrid.org
Keywords
Vancomycin, interference, immunoassay, therapeutic drug monitoringAbstract
Introduction: Vancomycin is a glycopeptide antibiotic indicated for the treatment of infections caused by methicillin-resistant Staphylococcus aureus. Appropriate vancomycin therapeutic drug monitoring is an essential exercise to improve the achievement of the target therapeutic levels.
Case description: An 87-year-old female was admitted with diagnosis of endocarditis. She was started on antibiotic therapy with intravenous vancomycin. The first vancomycin level registered in our hospital was 36.4 µg/ml. Because this value exceeded the critical threshold (15–20 µg/ml) the prescription was interrupted. New vancomycin concentration tests were indicated for the next days with 65.8 µg/ml, 73 µg/ml, 55.1 µg/ml, 77.9 µg/ml and 100 µg/ml results. Two samples were reanalysed in Hospital Universitario La Paz and were undetectable. Our Clinical Analysis Department found an analytical interference; however, the responsible molecule could not be identified, so the clinical team changed antibiotic treatment to daptomycin, and the infectious condition of the patient improved.
Conclusions: It is recommended that clinicians have a high index of suspicion to investigate cases where drug concentrations do not correlate with clinical expectations. Healthcare professionals need to understand that occasional interference still occurs due to the binding of proteins.
References
- Patel S, Preuss CV, Bernice F. Vancomycin. 2024; In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-.
- Van Der Heggen T, Buyle FM, Claus B, Somers A, Schelstraete P, De Paepe P, et al. Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life. Int J Clin Pharm 2021;43:1394–1403. doi: 10.1007/s11096-021-01266-7
- Cheng X, Ma J, Su J. An overview of analytical methodologies for determination of vancomycin in human plasma. Molecules 2022;27:7319. doi: 10.3390/molecules27217319
- Tsoi V, Bhayana V, Bombassaro AM, Tirona RG, Kittanakom S. Falsely elevated vancomycin concentrations in a patient not receiving vancomycin. Pharmacotherapy 2019;39:778–782. doi: 10.1002/phar.2279
- Singer B, Stevens RW, Westley BP, Nicolau DP. Falsely elevated vancomycin-concentration values from enzyme immunoassay leading to treatment failure. Am J Health Syst Pharm 2020;77:9–13. doi: 10.1093/ajhp/zxz258
- Rice ML, Go JR, Rivera CG, Zeuli JD, Saleh OA, Baumann NA, et al. Unexpected vancomycin pharmacokinetic profile secondary to macromolecular complexing: a case series. Ther Drug Monit 2021;43:696–700. doi: 10.1097/FTD.0000000000000888
- Smelter DF, Trisler MJ, McCreary EK, Baker M, Copeland K, Dilworth TJ, et al. Long-acting lipoglycopeptides can interfere with vancomycin therapeutic drug monitoring. J Clin Pharmacol 2022;62:472–478. doi: 10.1002/jcph.1975
- Simons SA, Molinelli AR, Sobhani K, Rainey PM, Hoofnagle AN. Two cases with unusual vancomycin measurements. Clin Chem 2009;55:578–580. doi: 10.1373/clinchem.2008.112946
- Westergreen-Thorne M, Lee SY, Shah N, Dodd A. When not to trust therapeutic drug monitoring. Oxf Med Case Reports 2016;2016:omw064. doi: 10.1093/omcr/omw064
- Tang NY, Walewski K, Carey-Ballough R, Sykes E, Sun Q. A suspected case of falsely low digoxin and vancomycin concentrations caused by free kappa light chains with PETINIA method. Pract Lab Med 2022;30:e00277. doi: 10.1016/j.plabm.2022.e00277
- Elzieny M, Fisher JA, Sims MD, Lauter CB, Carey-Ballough RA, Sun Q. Falsely decreased vancomycin caused by rheumatoid factor: a case report. Clin Chim Acta 2023;548:117460. doi: 10.1016/j.cca.2023.117460
- Pokhriyal SC, Tan EFS, Bhatt PK, Khan AA, Pasha MN, Pierre L, et al. Assay interference causing persistently elevated vancomycin levels leading to treatment failure and fatal outcome. Cureus 2024;16:e61943. doi: 10.7759/cureus.61943